Tarsus Pharmaceuticals, Inc. (TARS)

From the record

Tarsus Pharmaceuticals, Inc.'s filings since 2020 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Tarsus Pharmaceuticals, Inc.'s 6 filed years say what it did: it rose in 2 of 4 years; the deepest fall was 69% from fiscal 2021 to fiscal 2023; net income was positive in 0 of 6 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Tarsus Pharmaceuticals, Inc. lost about 19 cents for every dollar of shareholders' money. Leverage: it owed about 39 cents per dollar of assets, and net share issuance: its share count grew 11.1% over the year (the filed statements).

From the record

Tarsus Pharmaceuticals, Inc.'s standing among 102 graded names in its industry family: revenue of $451 million in fiscal 2025 ranks in the top 14% by size; a net margin of -14.7% ranks in the top 26%; revenue growth of 159.5% a year over the last 3 filed years ranks in the top 9% (its annual reports).

From the record

Tarsus Pharmaceuticals, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Azamian, Bobak R. (President/CEO and Board Chair, as filed), filing under that title since 2020-10-15, 6.1 years (top 34% of its family); the 15 officers and directors filing in the last fifteen months have been on the record a median of 5.8 years (top 37%); 5 officer or director changes were reported on Form 8-K since 2023-11-13, against the 15 people in charge now (top 30%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Tarsus Pharmaceuticals, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $186 million against debt of $72 million leaves 20.2% of its assets as net cash, bottom 38% of its family; cash from operations less capital spending is -4.9% of revenue (top 20%); research spending of 14.3% of revenue (bottom 9%) (its annual report).

From the record

Tarsus Pharmaceuticals, Inc.'s growth drivers, from the filed years to fiscal 2025: the newest year grew 146.9% (top 16%); research spending grew 14.7% a year (top 25%); capital spending grew 169% a year (top 2%) (its annual reports). Tarsus Pharmaceuticals, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Tarsus Pharmaceuticals, Inc.'s newest year against its own record: revenue of $451 million in fiscal 2025 came in 7.3% below the $487 million its prior three years' pace pointed to (bottom 33% of its family); net income of $66 million against a prior three-year average of $105 million (top 33%); a net margin of -14.7% against losses larger than its revenue before (top 31%) (its annual reports).